Bio-Thera Follows EU Bevacizumab Biosimilar Filing With FDA Goal Date

Biosimilar Now Accepted For Filing With Three Major Regulators

 
• By Dean Rudge
China USA or United States trade and American tariffs conflict with two opposing trading partners as an economic import and exports dispute concept with 3D illustration elements
Bio-Thera Solutions is looking to break into the blockbuster US bevacizumab market as part of its global strategy. • Source: Shutterstock

More from Biosimilars

More from Products